Vanderbilt University, Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, 7465 MRB IV, 2213 Garland Avenue, Nashville, TN 37232-0475, USA.
Expert Opin Drug Metab Toxicol. 2010 Feb;6(2):225-35. doi: 10.1517/17425250903512955.
Type 2 diabetes mellitus (T2DM) is increasingly prevalent throughout the world; controlling glycemia is an important part of preventing serious complications of diabetes. Sulfonylureas have been used in the treatment of type 2 diabetes for many years.
This article reviews the pharmacological and clinical aspects of glimepiride, a second-generation sulfonylurea. Literature search was conducted in PubMed, and articles selected for relevance to pharmacology or clinical efficacy data from 1994 to 2009, with older references sought as indicated.
Pharmacology of glimepiride, data regarding clinical efficacy, key comparisons to other agents and emerging concepts related to glimepiride are discussed.
Therapy with glimepiride improves the relative insulin secretory deficit found in T2DM, has antihyperglycemic efficacy equal to other secretagogues with reduced potential for hypoglycemia and may have additional actions contributing to glycemic control in T2DM.
2 型糖尿病(T2DM)是越来越普遍在世界各地,控制血糖是预防糖尿病严重并发症的一个重要部分。磺酰脲类药物已被用于治疗 2 型糖尿病多年。
在这篇综述中讨论了格列美脲,第二代磺酰脲类药物的药理学和临床方面。文献检索在 PubMed 进行,选择了与 1994 年至 2009 年的药理学或临床疗效数据相关的文章,并根据需要寻找了较旧的参考文献。
格列美脲的药理学、关于临床疗效的数据、与其他药物的关键比较以及与格列美脲相关的新出现的概念。
格列美脲治疗可改善 T2DM 中发现的相对胰岛素分泌不足,具有与其他促分泌剂相当的抗高血糖疗效,低血糖的潜在风险降低,并且可能对 T2DM 的血糖控制有额外作用。